Fincar is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). Fincar is recommended for use in adult males.

The recommended dose is 5 mg once a day with or without meals. Although early improvement is seen, at least 6-12 months of therapy with Fincar, it may be necessary in some patients to assess whether a beneficial response has been achieved. Periodic follow up evaluations should be performed to determine whether a clinical response has occurred. Dose adjustment is not required in geriatric individuals with impaired renal function. No dose adjustment is required in impaired hepatic function. Since Finasteride is metabolised extensively in the liver, the drug should be used with caution in patients with hepatic impairment.

Since not all patients demonstrate a response to Fincar, patients with a large residual urine volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy. These patients may not be candidates for this therapy.

Caution should be used in the administration of Fincar in those patients with liver abnormalities, as finasteride is metabolised extensively in the liver. Pregnant women, and women wanting to become pregnant,should not handle crushed or broken Fincar tablets and avoid exposure to the semen of men on Fincar because of the potential risk to the male foetus.